Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 26, 2004

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission File Number 000-26137

 


 

drugstore.com, inc.

(Exact name of registrant as specified in its charter)

 


 

Delaware   04-3416255

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

13920 Southeast Eastgate Way, Suite 300, Bellevue, Washington 98005

(Address of principal executive offices including zip code)

 

(425) 372-3200

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨.

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes  x    No  ¨.

 

As of October 29, 2004, the registrant had 80,720,214 shares of common stock outstanding.

 



Table of Contents

DRUGSTORE.COM, INC.

 

FORM 10-Q

 

For the three- and nine-months ended September 26, 2004

 

INDEX

 

         Page

PART I.

  FINANCIAL INFORMATION    3

Item 1.

       Financial Statements (unaudited):    3
        

Condensed Consolidated Statements of Operations

   3
        

Condensed Consolidated Balance Sheets

   4
        

Condensed Consolidated Statements of Cash Flows

   5
        

Notes to Condensed Consolidated Financial Statements

   6

Item 2.

       Management’s Discussion and Analysis of Financial Condition and Results of Operations    16

Item 3.

       Qualitative and Quantitative Disclosures About Market Risk    26

Item 4.

       Controls and Procedures    26

PART II.

  OTHER INFORMATION     

Item 1.

       Legal Proceedings    27

Item 2.

       Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities    27

Item 3.

       Defaults Upon Senior Securities    27

Item 4.

       Submission of Matters to a Vote of Security Holders    27

Item 5.

       Other Information    27

Item 6.

       Exhibits    28

Signatures

   29

Certifications

 

2


Table of Contents

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

DRUGSTORE.COM, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

 

     Three Months Ended

    Nine Months Ended

 
     September 26,
2004


    September 28,
2003
(restated)


    September 26,
2004


    September 28,
2003
(restated)


 

Net sales

   $ 84,287     $ 59,843     $ 256,493     $ 175,150  

Costs and expenses:

                                

Cost of sales

     67,702       47,704       204,231       140,578  

Fulfillment and order processing

     9,590       7,091       28,406       21,319  

Marketing and sales

     5,749       4,718       18,212       12,470  

Technology and content

     2,256       1,928       6,644       6,317  

General and administrative

     4,287       2,688       11,342       8,332  

Amortization of intangible assets

     1,072       407       3,156       1,116  

Stock-based compensation (1)(2)

     56       1,462       615       1,737  

Impairment of goodwill and other intangible assets

     26,480       —         26,480       —    
    


 


 


 


Total costs and expenses

     117,192       65,998       299,086       191,869  
    


 


 


 


Operating loss

     (32,905 )     (6,155 )     (42,593 )     (16,719 )

Interest income, net

     62       132       221       510  
    


 


 


 


Net loss

   $ (32,843 )   $ (6,023 )   $ (42,372 )   $ (16,209 )
    


 


 


 


Basic and diluted net loss per share

   $ (0.43 )   $ (0.09 )   $ 0.56     $ (0.24 )
    


 


 


 


Weighted average shares outstanding used to compute basic and diluted net loss per share

     76,493,041       69,353,932       75,474,903       68,935,822  
    


 


 


 



(1)    As previously disclosed in our annual report on Form 10-K for the fiscal year ended December 28, 2003, the amounts for the three- and nine-month periods ended September 28, 2003 have been restated to include an additional $1.3 million in stock-based compensation recorded as a result of modifications of certain stock option grants for terminated employees.

(2)    Set forth below are the amounts of stock-based compensation that, if recorded by operating function, would be classified in the Statements of Operations as follows:

        

       

Fulfillment and order processing

   $ 5     $ 29     $ 34     $ 108  

Marketing and sales

     1       819       63       839  

Technology and content

     42       84       74       182  

General and administrative

     8       530       444       608  
    


 


 


 


Total

   $ 56     $ 1,462     $ 615     $ 1,737  
    


 


 


 


 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

DRUGSTORE.COM, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

     September 26,
2004


    December 28,
2003


 
     (unaudited)     (audited)  
Assets                 

Current assets:

                

Cash and cash equivalents

   $ 21,330     $ 5,285  

Marketable securities

     12,394       38,287  

Accounts receivable, net of allowances

     29,618       24,896  

Inventories

     16,006       13,647  

Prepaid marketing expenses

     2,290       2,291  

Other current assets

     3,559       3,231  
    


 


Total current assets

     85,197       87,637  

Fixed assets, net

     14,831       14,280  

Goodwill, net

     30,168       53,077  

Other intangible assets, net

     12,308       19,011  

Prepaid marketing expenses

     8,588       10,305  

Deposits and other assets

     102       102  
    


 


Total assets

   $ 151,194     $ 184,412  
    


 


Liabilities and Stockholders’ Equity                 

Current liabilities:

                

Accounts payable

   $ 50,180     $ 46,964  

Accrued compensation

     2,773       2,932  

Accrued marketing expenses

     2,333       1,870  

Other current liabilities

     4,402       3,043  

Current portion of capital lease obligations

     631       785  
    


 


Total current liabilities

     60,319       55,594  

Capital lease obligations, less current portion

     423       600  

Commitments and contingencies

                

Stockholders’ equity:

                

Preferred stock, $.0001 par value, 10,000,000 shares authorized, no shares outstanding

                

Common stock, $.0001 par value, stated at amounts paid in: 250,000,000 shares authorized; 80,568,989 and 77,361,026 shares issued and outstanding

     801,594       797,534  

Deferred stock-based compensation

     (89 )     (635 )

Accumulated deficit

     (711,053 )     (668,681 )
    


 


Total stockholders’ equity

     90,452       128,218  
    


 


Total liabilities and stockholders’ equity

   $ 151,194     $ 184,412  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

4


Table of Contents

DRUGSTORE.COM, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

     Nine Months Ended

 
     September 26,
2004


    September 28,
2003


 

Operating Activities:

                

Net loss

   $ (42,372 )   $ (16,209 )

Adjustments to reconcile net loss to net cash used in operating activities:

                

Non-cash expenses:

                

Depreciation

     5,571       4,784  

Amortization of marketing and sales agreements

     1,718       1,717  

(Gain) loss on disposal of fixed assets

     (19 )     44  

Amortization of intangible assets

     3,156       1,116  

Stock-based compensation

     615       1,737  

Impairment of goodwill and other intangible assets

     26,480       —    

Litigation settlement

     475       —    

Changes in:

                

Accounts receivable

     (4,722 )     (1,218 )

Inventories

     (2,359 )     (1,467 )

Prepaid marketing expenses

     —         306  

Other current assets

     (328 )     122  

Accounts payable and accrued expenses

     1,536       (1,323 )

Other

     —         106  
    


 


Net cash used in operating activities

     (10,249 )     (10,285 )
    


 


Investing Activities:

                

Purchases of marketable securities

     (17,353 )     (38,994 )

Sales of marketable securities

     43,246       45,400  

Business acquisition, net of cash received

     —         (1,365 )

Purchase of fixed assets

     (3,258 )     (2,470 )
    


 


Net cash provided by investing activities

     22,635       2,571  
    


 


Financing Activities:

                

Proceeds from exercise of stock options and employee stock purchase plan

     3,991       1,637  

Proceeds from asset financing

     —         615  

Principal payments on capital lease obligations

     (332 )     (834 )
    


 


Net cash provided by financing activities

     3,659       1,418  
    


 


Net increase (decrease) in cash and cash equivalents

     16,045       (6,296 )

Cash and cash equivalents at beginning of period

     5,285       19,384  
    


 


Cash and cash equivalents at end of period

   $ 21,330     $ 13,088